Literature DB >> 16882112

Lithium and venlafaxine interaction: a case of serotonin syndrome.

J Adan-Manes1, J Novalbos, R López-Rodríguez, J L Ayuso-Mateos, F Abad-Santos.   

Abstract

Serotonin syndrome, which occurs as a result of enhanced serotonin concentration in the central nervous system, is a well-known adverse effect of serotonin-active medications. The concomitant use of antidepressant drugs associated with lithium as a co-adjuvant seems to increase the risk of this adverse reaction. We report a case of the serotonin syndrome during treatment with lithium and venlafaxine, an antidepressant with a dual selective re-uptake inhibition mechanism, and review the literature for similar cases. A 71-year-old woman developed serotonin syndrome while receiving treatment with moderate doses of lithium and venlafaxine for refractory depression. She had been taking higher doses of venlafaxine during the previous months with no significant secondary effects. Use of the Naranjo adverse drug reaction probability algorithm indicated a probable relationship between serotonin syndrome and treatment with lithium and venlafaxine.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16882112     DOI: 10.1111/j.1365-2710.2006.00745.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  3 in total

Review 1.  Clinically significant drug interactions with newer antidepressants.

Authors:  Edoardo Spina; Gianluca Trifirò; Filippo Caraci
Journal:  CNS Drugs       Date:  2012-01-01       Impact factor: 5.749

2.  Serotonin Syndrome following Introduction of Venlafaxine following Withdrawal of Phenelzine: Implications for Drug Washout Periods.

Authors:  Sarah J Yates; Niraj Ahuja; Sarah E Gartside; R Hamish McAllister-Williams
Journal:  Ther Adv Psychopharmacol       Date:  2011-08

3.  Lack of Effect of Vortioxetine on the Pharmacokinetics and Pharmacodynamics of Ethanol, Diazepam, and Lithium.

Authors:  Grace Chen; George G Nomikos; John Affinito; Zhen Zhao
Journal:  Clin Pharmacokinet       Date:  2016-09       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.